BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Global biopharmaceutical leaders continue to make significant 
 strides in retinal disease treatments\; as Bayer and Regeneron make headw
 ay with its high-dose version of Eylea (Eylea HD)\, Roche's Vabysmo is pr
 oviding strong competition and has rapidly increased its market share acr
 oss wet AMD and DME.\n\nAdditionally\, biotechs are pioneering new breakt
 hroughs such as Outlook Therapeutics developing bevacizumab for FDA appro
 val in ophthalmic indications\, while Ocular Therapeutix progresses innov
 ative sustained-release drug delivery systems to extend treatment interva
 ls and enhance patient outcomes.\n\nThe 2025 Wet AMD and Diabetic Eye Dis
 ease Drug Summit is the only industry-led event dedicated to exploring th
 e latest advancements\, strategic collaborations\, and cutting-edge resea
 rch driving the field of retinal disease treatment forward.\n\nJoin a dyn
 amic community of 70+ global leaders\, including translational\, clinical
 \, and commercial experts as they gather at this premier summit. Attendee
 s will gain unparalleled insights into emerging therapies\, adaptive tria
 l designs\, and the latest clinical studies aimed at improving treatment 
 efficacy and patient care.\n\nDate and Time: Tuesday\, 18 March 2025 at 0
 8:00 to Thursday\, 20 March 2025 at 16:20\n
DTEND:20250320T162000
DTSTAMP:20260512T223119Z
DTSTART:20250318T080000
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, Massach
 usetts\, 02116\,
SEQUENCE:0
SUMMARY:Global biopharmaceutical leaders continue to make significant stri
 des in retinal disease treatments\; as Bayer and Regeneron make headway w
 ith its h...
UID:c9f21004-0e7d-4e02-b8d1-5ee3199917e5
END:VEVENT
END:VCALENDAR